No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial

J.P. Ferreira; N. Girerd; H.P. Brunner-La Rocca; P. Pellicori; J.G. Cleland; P. Rossignol; F. Zannad

doi:10.1016/j.acvd.2021.10.003

No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial

J.P. Ferreira^*, N. Girerd, H.P. Brunner-La Rocca, P. Pellicori, J.G. Cleland, P. Rossignol, F. Zannad

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	814-817
Number of pages	4
Journal	Archives of Cardiovascular Diseases
Volume	114
Issue number	12
DOIs	https://doi.org/10.1016/j.acvd.2021.10.003
Publication status	Published - 1 Dec 2021

Keywords

SARS-CoV-2
COVID-19
Spironolactone
RECEPTOR
ACE2
RISK

Access to Document

10.1016/j.acvd.2021.10.003

Cite this

@article{3e6eedce001a4eb380ddb7ec382dabef,

title = "No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial",

keywords = "SARS-CoV-2, COVID-19, Spironolactone, RECEPTOR, ACE2, RISK",

author = "J.P. Ferreira and N. Girerd and {Brunner-La Rocca}, H.P. and P. Pellicori and J.G. Cleland and P. Rossignol and F. Zannad",

year = "2021",

month = dec,

day = "1",

doi = "10.1016/j.acvd.2021.10.003",

language = "English",

volume = "114",

pages = "814--817",

journal = "Archives of Cardiovascular Diseases",

issn = "1875-2136",

publisher = "Elsevier Masson",

number = "12",

}

No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. / Ferreira, J.P.; Girerd, N.; Brunner-La Rocca, H.P.; Pellicori, P.; Cleland, J.G.; Rossignol, P.; Zannad, F.

In: Archives of Cardiovascular Diseases, Vol. 114, No. 12, 01.12.2021, p. 814-817.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial

AU - Ferreira, J.P.

AU - Girerd, N.

AU - Brunner-La Rocca, H.P.

AU - Pellicori, P.

AU - Cleland, J.G.

AU - Rossignol, P.

AU - Zannad, F.

PY - 2021/12/1

Y1 - 2021/12/1

KW - SARS-CoV-2

KW - COVID-19

KW - Spironolactone

KW - RECEPTOR

KW - ACE2

KW - RISK

U2 - 10.1016/j.acvd.2021.10.003

DO - 10.1016/j.acvd.2021.10.003

M3 - Comment/Letter to the editor

C2 - 34772647

VL - 114

SP - 814

EP - 817

JO - Archives of Cardiovascular Diseases

JF - Archives of Cardiovascular Diseases

SN - 1875-2136

IS - 12

ER -